Records 1 - 3
| Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer.
Cancers 2021 Mar 13 (6): .
Zhu Guangsheng, Ren Dian, Lei Xi, Shi Ruifeng, Zhu Shuai, Zhou Ning, Zu Lingling, Mello Ramon Andrade De, Chen Jun, Xu So
| Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Scientific reports 2020 Nov 10 (1): 20243.
Shang Yanhong, Li Xiaofang, Liu Weiwei, Shi Xiaoliang, Yuan Shaohua, Huo Ran, Fang Guotao, Han Xiao, Zhang Jingnan, Wang Kunjie, Dou Zhengyue, Zhang Yan, Zang Aimin, Zhang L
| PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab.
Lung cancer (Amsterdam, Netherlands) 2020 Nov .
Wang Haiyong, Shan Qinge, Guo Jun, Han Xiao, Zhao Chenglong, Li Huijuan, Wang Zheh